Fragile X syndrome: a psychiatric perspective.
Fragile X syndrome (FXS) is associated with a complex but relatively consistent psychiatric phenotype. Recent research has suggested neural substrates for the behavioral abnormalities typically seen in FXS, and enhanced treatment strategies for managing disabling psychiatric comorbidity. While disease-specific, and possibly disease-modifying, therapeutics are being developed for FXS, currently available psychiatric medications can provide significant symptomatic relief of the hyperactivity, anxiety disorders, and affective disturbances often seen in the course of FXS. However, patients with fragile X may be especially susceptible to the psychiatric side effects of these medications, requiring particular care in prescribing. Recent findings concerning disease mechanisms and treatment strategies are reviewed from the perspective of a clinical psychiatrist, in an effort to enhance conventional pharmacotherapy of FXS.
FRAXA Research Foundation, Newburyport, MA 01950, USA. mtranfaglia@fraxa.org
Michael R
MR
Tranfaglia
D000818:Animals; D001008:Anxiety Disorders / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D001289:Attention Deficit Disorder with Hyperactivity / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D001519:Behavior / Q000502:physiology; D005260:Female; D005600:Fragile X Syndrome / Q000150:complications / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D008297:Male; D051379:Mice; D019964:Mood Disorders / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D010641:Phenotype